

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**昭衍**

**JOINN**

**JOINN LABORATORIES (CHINA) CO., LTD.**

**北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

*(Stock Code: 6127)*

**REFERENCE IS MADE TO THE ANNOUNCEMENT ISSUED BY JOINN LABORATORIES (CHINA) CO., LTD. (THE "COMPANY"), TOGETHER WITH ITS SUBSIDIARIES, THE "GROUP") ON 5 FEBRUARY 2024 IN RELATION TO THE CONTINUING CONNECTED TRANSACTIONS CONTEMPLATED IN: (I) THE 2024 STADSON RESEARCH AND DEVELOPMENT SERVICE FRAMEWORK AGREEMENT; (II) THE 2024 SHENGTONG SOFTWARE SERVICE FRAMEWORK AGREEMENT, AND (III) CONNECTED TRANSACTION CONTEMPLATED IN THE ESTABLISHMENT OF PARTNERSHIP FUND (THE "PARTNERSHIP FUND"). UNLESS OTHERWISE SPECIFIED IN THIS ANNOUNCEMENT, TERMS USED HEREIN SHALL HAVE THE SAME MEANINGS AS THOSE DEFINED IN THE ANNOUNCEMENT.**

Reference is made to the announcement issued by JOINN Laboratories (China) Co., Ltd. (the "Company", together with its subsidiaries, the "Group") on 5 February 2024 in relation to the continuing connected transactions contemplated in: (i) the 2024 Staidson Research and Development Service Framework Agreement; (ii) the 2024 Shengtong Software Service Framework Agreement, and (iii) connected transaction contemplated in the establishment of Partnership Fund (the "Partnership Fund"). Unless otherwise specified in this announcement, terms used herein shall have the same meanings as those defined in the Announcement.

The Company wishes to provide further information in relation to the 2024 Staidson Research and Development Service Framework Agreement and the 2024 Shengtong Software Service Framework Agreement as follows:

**2024年1月1日至2024年12月31日止，本公司與Staidson Research and Development Service Framework Agreement及Shengtong Software Service Framework Agreement的持續關連交易。**

### **Pricing policy**

The Company will provide services to Staidson on a project basis and enter into separate agreement for each research and development project. For the pricing policy of the service fee, the Company takes into account: (i) the cost (including raw materials and labour costs) in connection with the services to be provided under each research project; (ii) the feature, complexity, length and value of the drug research and development services to be provided at various stages; (iii) the prices charged for previous transactions of a similar kind; and (iv) the price of services/projects of similar provided by the Company to other independent third-party customers. In deciding the service fees, the Company will adopt a cost plus profit margin approach, and make reference to quotations for similar projects provided to the Company by approximately one to three independent third-party customers. The profit margin for each project will vary depending on the costs, time required, feature and complexity of the services



***Payment terms***

The Company will make payment at different stages of the project when the software developed by Shengtong fulfills the requirements as set by Company, and the amount payable by the Company will vary depending on the scale and feature of each project. Save for the above, the content of the Announcement remains unchanged.

By order of the Board  
Feng Yuxia  
Chairperson

Beijing, the PRC, 27 February 2024

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*